Switch theme
Sign up to access all valuation multiples
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
1984
15K+
LTM Revenue $2.3B
LTM EBITDA $376M
$4.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ICU Medical has a last 12-month revenue (LTM) of $2.3B and a last 12-month EBITDA of $376M.
In the most recent fiscal year, ICU Medical achieved revenue of $2.4B and an EBITDA of $260M.
ICU Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ICU Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.3B | XXX | $2.4B | XXX | XXX | XXX |
| Gross Profit | $835M | XXX | $825M | XXX | XXX | XXX |
| Gross Margin | 37% | XXX | 35% | XXX | XXX | XXX |
| EBITDA | $376M | XXX | $260M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 11% | XXX | XXX | XXX |
| EBIT | $301M | XXX | $97.4M | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $157M | XXX | -$118M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | -5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ICU Medical's stock price is $135.
ICU Medical has current market cap of $3.3B, and EV of $4.6B.
See ICU Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.6B | $3.3B | XXX | XXX | XXX | XXX | $6.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ICU Medical has market cap of $3.3B and EV of $4.6B.
ICU Medical's trades at 1.9x EV/Revenue multiple, and 17.8x EV/EBITDA.
Equity research analysts estimate ICU Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ICU Medical has a P/E ratio of 21.1x.
See valuation multiples for ICU Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.3B | XXX | $3.3B | XXX | XXX | XXX |
| EV (current) | $4.6B | XXX | $4.6B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 12.3x | XXX | 17.8x | XXX | XXX | XXX |
| EV/EBIT | 15.4x | XXX | 47.6x | XXX | XXX | XXX |
| EV/Gross Profit | 5.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.1x | XXX | -28.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 40.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialICU Medical's last 12 month revenue growth is -5%
ICU Medical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $48K for the same period.
ICU Medical's rule of 40 is 6% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ICU Medical's rule of X is 5% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ICU Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -5% | XXX | -5% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 23% | XXX | XXX | XXX |
| Rule of 40 | 6% | XXX | 6% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 5% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $48K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ICU Medical acquired XXX companies to date.
Last acquisition by ICU Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . ICU Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ICU Medical founded? | ICU Medical was founded in 1984. |
| Where is ICU Medical headquartered? | ICU Medical is headquartered in United States of America. |
| How many employees does ICU Medical have? | As of today, ICU Medical has 15K+ employees. |
| Who is the CEO of ICU Medical? | ICU Medical's CEO is Mr. Vivek Jain. |
| Is ICU Medical publicy listed? | Yes, ICU Medical is a public company listed on NAS. |
| What is the stock symbol of ICU Medical? | ICU Medical trades under ICUI ticker. |
| When did ICU Medical go public? | ICU Medical went public in 1992. |
| Who are competitors of ICU Medical? | Similar companies to ICU Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of ICU Medical? | ICU Medical's current market cap is $3.3B |
| What is the current revenue of ICU Medical? | ICU Medical's last 12 months revenue is $2.3B. |
| What is the current revenue growth of ICU Medical? | ICU Medical revenue growth (NTM/LTM) is -5%. |
| What is the current EV/Revenue multiple of ICU Medical? | Current revenue multiple of ICU Medical is 2.0x. |
| Is ICU Medical profitable? | Yes, ICU Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ICU Medical? | ICU Medical's last 12 months EBITDA is $376M. |
| What is ICU Medical's EBITDA margin? | ICU Medical's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of ICU Medical? | Current EBITDA multiple of ICU Medical is 12.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
